Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Evaluation of Intra-Abdominal Fat in Patients With Type 2 Diabetes Using a Non-Invasive Method
Evaluation of Intra-Abdominal Fat Contents in Patients With Type 2 Diabetes Using a Novel Non-Invasive Method of Bioelectric Impedance
Status: Enrolling
Updated:  2/28/2017
Joslin Diabetes Center
mi
from
Boston, MA
Evaluation of Intra-Abdominal Fat in Patients With Type 2 Diabetes Using a Non-Invasive Method
Evaluation of Intra-Abdominal Fat Contents in Patients With Type 2 Diabetes Using a Novel Non-Invasive Method of Bioelectric Impedance
Status: Enrolling
Updated: 2/28/2017
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
Acromegaly Treatment Quality of Life Study
Effect of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life
Status: Enrolling
Updated:  3/1/2017
Massachusetts General Hospital
mi
from
Boston, MA
Acromegaly Treatment Quality of Life Study
Effect of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life
Status: Enrolling
Updated: 3/1/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Egrifta Replacement and Sleep Disordered Breathing
Egrifta Replacement and Sleep Disordered Breathing
Status: Enrolling
Updated:  3/2/2017
Johns Hopkins Sleep Disorders Center
mi
from
Baltimore, MD
Egrifta Replacement and Sleep Disordered Breathing
Egrifta Replacement and Sleep Disordered Breathing
Status: Enrolling
Updated: 3/2/2017
Johns Hopkins Sleep Disorders Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
IR and Microvascular Blood Flow in SCI
Insulin Resistance and Microvascular Blood Flow in Spinal Cord Injury
Status: Enrolling
Updated:  3/6/2017
James J Peters VA Medical Center
mi
from
Bronx, NY
IR and Microvascular Blood Flow in SCI
Insulin Resistance and Microvascular Blood Flow in Spinal Cord Injury
Status: Enrolling
Updated: 3/6/2017
James J Peters VA Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Mediterranean Diet and Protein-Sparing Modified Diet for Metabolic Syndrome in Liver Transplant Recipients
The Safety and Efficacy of Mediterranean Diet and Protein-Sparing Modified Diet on Obesity and Metabolic Syndrome in Liver Transplant Recipients: A Randomized Clinical Trial
Status: Enrolling
Updated:  3/13/2017
Cleveland Clinic
mi
from
Cleveland, OH
Mediterranean Diet and Protein-Sparing Modified Diet for Metabolic Syndrome in Liver Transplant Recipients
The Safety and Efficacy of Mediterranean Diet and Protein-Sparing Modified Diet on Obesity and Metabolic Syndrome in Liver Transplant Recipients: A Randomized Clinical Trial
Status: Enrolling
Updated: 3/13/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
Status: Enrolling
Updated:  3/20/2017
Brigham and Women's Hosp
mi
from
Boston, MA
The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
Status: Enrolling
Updated: 3/20/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Infant Nutrition and Risk of Celiac Disease
Infant Nutrition and Risk of Celiac Disease: Proposal for an Intervention, Prospective Multicenter Study
Status: Enrolling
Updated:  3/21/2017
Massachusetts General Hospital - East
mi
from
Charlestown, MA
Infant Nutrition and Risk of Celiac Disease
Infant Nutrition and Risk of Celiac Disease: Proposal for an Intervention, Prospective Multicenter Study
Status: Enrolling
Updated: 3/21/2017
Massachusetts General Hospital - East
mi
from
Charlestown, MA
Click here to add this to my saved trials
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated:  3/22/2017
New England Diabetes and Endocrinology Center (NEDEC)
mi
from
Waltham, MA
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated: 3/22/2017
New England Diabetes and Endocrinology Center (NEDEC)
mi
from
Waltham, MA
Click here to add this to my saved trials
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated:  3/22/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated: 3/22/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated:  3/22/2017
Albany Medical College Division of Community Endocrinology
mi
from
Albany, NY
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated: 3/22/2017
Albany Medical College Division of Community Endocrinology
mi
from
Albany, NY
Click here to add this to my saved trials
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated:  3/22/2017
Winnipeg Clinic
mi
from
Winnipeg,
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated: 3/22/2017
Winnipeg Clinic
mi
from
Winnipeg,
Click here to add this to my saved trials
Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism
Role of FSH in Human Gonadal Development
Status: Enrolling
Updated:  3/29/2017
Massachusetts General Hospital
mi
from
Boston, MA
Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism
Role of FSH in Human Gonadal Development
Status: Enrolling
Updated: 3/29/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism
Positive Clinical and Hormonal Effects of Ethinylestradiol Combined With Drospirenone (EE/DRSP) in Women With Polycystic Ovary Syndrome (PCOS): Impact of Body Weight and Relevance to Hyperandrogenism
Status: Enrolling
Updated:  3/30/2017
Woman's Hospital
mi
from
Baton Rouge, LA
Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism
Positive Clinical and Hormonal Effects of Ethinylestradiol Combined With Drospirenone (EE/DRSP) in Women With Polycystic Ovary Syndrome (PCOS): Impact of Body Weight and Relevance to Hyperandrogenism
Status: Enrolling
Updated: 3/30/2017
Woman's Hospital
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases
Treatment of Early Infantile-Onset Lysosomal Storage Diseases With Fetal Umbilical Cord Blood (UCB) Transplantation
Status: Enrolling
Updated:  4/3/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases
Treatment of Early Infantile-Onset Lysosomal Storage Diseases With Fetal Umbilical Cord Blood (UCB) Transplantation
Status: Enrolling
Updated: 4/3/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases
Treatment of Early Infantile-Onset Lysosomal Storage Diseases With Fetal Umbilical Cord Blood (UCB) Transplantation
Status: Enrolling
Updated:  4/3/2017
Duke University Medical Center Pediatric Blood and Marrow Transplant
mi
from
Durham, NC
Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases
Treatment of Early Infantile-Onset Lysosomal Storage Diseases With Fetal Umbilical Cord Blood (UCB) Transplantation
Status: Enrolling
Updated: 4/3/2017
Duke University Medical Center Pediatric Blood and Marrow Transplant
mi
from
Durham, NC
Click here to add this to my saved trials
Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk
Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk
Status: Enrolling
Updated:  4/3/2017
Ohio State University
mi
from
Columbus, OH
Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk
Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk
Status: Enrolling
Updated: 4/3/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI Refractory Thyroid Cancers With the Combination of BRAF Inhibitor Vemurafenib and Anti-ErbB3 Antibody KTN3379: A Pilot Study With a Phase 1 Run-in
Status: Enrolling
Updated:  4/6/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI Refractory Thyroid Cancers With the Combination of BRAF Inhibitor Vemurafenib and Anti-ErbB3 Antibody KTN3379: A Pilot Study With a Phase 1 Run-in
Status: Enrolling
Updated: 4/6/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Processing Responses of Grains (PRO-Grains) Study
Effect of Intact vs. Highly Processed Whole Grains on Insulin Sensitivity and Other Cardiometabolic Risk Factors in Hyperinsulinemic Adults
Status: Enrolling
Updated:  4/10/2017
Children's Hospital Boston
mi
from
Boston, MA
Processing Responses of Grains (PRO-Grains) Study
Effect of Intact vs. Highly Processed Whole Grains on Insulin Sensitivity and Other Cardiometabolic Risk Factors in Hyperinsulinemic Adults
Status: Enrolling
Updated: 4/10/2017
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)
Registry of Patients Being Treated With Norditropin®, Recombinant Human Growth Hormone
Status: Enrolling
Updated:  4/11/2017
Novo Nordisk Investigational Site
mi
from
Plainsboro, NJ
An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)
Registry of Patients Being Treated With Norditropin®, Recombinant Human Growth Hormone
Status: Enrolling
Updated: 4/11/2017
Novo Nordisk Investigational Site
mi
from
Plainsboro, NJ
Click here to add this to my saved trials
Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)
Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism
Status: Enrolling
Updated:  4/17/2017
Massachusetts General Hospital
mi
from
Boston, MA
Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)
Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism
Status: Enrolling
Updated: 4/17/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Pilot Study of Strength Testing in Overweight Women With or Without Insulin Resistance
Pilot Study of Strength Testing in Overweight Women With or Without Insulin Resistance
Status: Enrolling
Updated:  4/19/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Pilot Study of Strength Testing in Overweight Women With or Without Insulin Resistance
Pilot Study of Strength Testing in Overweight Women With or Without Insulin Resistance
Status: Enrolling
Updated: 4/19/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).
Status: Enrolling
Updated:  4/20/2017
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Nashville, TN
Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).
Status: Enrolling
Updated: 4/20/2017
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Nashville, TN
Click here to add this to my saved trials
Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).
Status: Enrolling
Updated:  4/20/2017
Vanderbilt-Ingram Cancer Center at Franklin
mi
from
Nashville, TN
Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).
Status: Enrolling
Updated: 4/20/2017
Vanderbilt-Ingram Cancer Center at Franklin
mi
from
Nashville, TN
Click here to add this to my saved trials
Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).
Status: Enrolling
Updated:  4/20/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).
Status: Enrolling
Updated: 4/20/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study
Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study
Status: Enrolling
Updated:  4/20/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study
Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study
Status: Enrolling
Updated: 4/20/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study
Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study
Status: Enrolling
Updated:  4/20/2017
Washington Hospital Center
mi
from
Washington, D.C.,
Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study
Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study
Status: Enrolling
Updated: 4/20/2017
Washington Hospital Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Glycemic Index - Variability Among Individuals
Evaluation of Glycemic Index to Assess Diet Associated Chronic Disease Risk
Status: Enrolling
Updated:  4/24/2017
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
mi
from
Boston, MA
Glycemic Index - Variability Among Individuals
Evaluation of Glycemic Index to Assess Diet Associated Chronic Disease Risk
Status: Enrolling
Updated: 4/24/2017
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
mi
from
Boston, MA
Click here to add this to my saved trials
Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies
Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies
Status: Enrolling
Updated:  4/24/2017
Bristlecone Behavioral Health, Inc.
mi
from
Maple Grove, MN
Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies
Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies
Status: Enrolling
Updated: 4/24/2017
Bristlecone Behavioral Health, Inc.
mi
from
Maple Grove, MN
Click here to add this to my saved trials
Bioactive Plant Foods: Effects on Functional Bioavailability and Genomic Stability
Bioactive Plant Foods: Effects on Functional Bioavailability and Genomic Stability
Status: Enrolling
Updated:  4/24/2017
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
mi
from
Boston, MA
Bioactive Plant Foods: Effects on Functional Bioavailability and Genomic Stability
Bioactive Plant Foods: Effects on Functional Bioavailability and Genomic Stability
Status: Enrolling
Updated: 4/24/2017
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
mi
from
Boston, MA
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Birmingham, AL
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Little Rock, AR
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Iowa City, IA
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Louisville, KY
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Baltimore, MD
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Kansas City, MO
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Greenville, NC
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Greenville, NC
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Dallas, TX
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Houston, TX
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
San Antonio, TX
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
mi
from
Bruxelles,
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
mi
from
Bruxelles,
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated:  4/25/2017
Research Site
mi
from
The Bronx, NY
Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis
Status: Enrolling
Updated: 4/25/2017
Research Site
mi
from
The Bronx, NY
Click here to add this to my saved trials
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Status: Enrolling
Updated:  4/25/2017
Joslin Diabetes Center
mi
from
Boston, MA
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Status: Enrolling
Updated: 4/25/2017
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer
Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer
Status: Enrolling
Updated:  5/3/2017
Rebecca J Guigli
mi
from
Aurora, CO
Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer
Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer
Status: Enrolling
Updated: 5/3/2017
Rebecca J Guigli
mi
from
Aurora, CO
Click here to add this to my saved trials
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents (PHM3)
Status: Enrolling
Updated:  5/9/2017
Stanford University
mi
from
Stanford, CA
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents (PHM3)
Status: Enrolling
Updated: 5/9/2017
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials